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Background: While neuroimaging in ALS has gained unprecedented momentum in recent years, little progress 
has been made in the development of viable diagnostic, prognostic and monitoring markers. 
Objectives: To identify and discuss the common pitfalls in ALS imaging studies and to reﬂect on optimal study
designs based on pioneering studies. 
Methods: A “PubMed”-based literature search on ALS was performed based on neuroimaging-related key- 
words. Study limitations were systematically reviewed and classiﬁed so that stereotypical trends could be 
identiﬁed. 
Results: Common shortcomings, such as relatively small sample sizes, statistically underpowered study 
designs, lack of disease controls, poorly characterised patient cohorts and a large number of conﬂicting 
studies, remain a signiﬁcant challenge to the ﬁeld. Imaging data of ALS continue to be interpreted at a
group-level, as opposed to meaningful individual-patient inferences. 
Conclusions: A systematic, critical review of ALS imaging has identiﬁed stereotypical shortcomings, the 
lessons of which should be considered in the design of future prospective MRI studies. At a time when large
multicentre studies are underway a candid discussion of these factors is particularly timely. 
c © 2014 The Authors. Published by Elsevier Inc. 
This is an open access article under the CC BY-NC-ND license 
( http: // creativecommons.org / licenses / by-nc-nd / 3.0 / ). . Introduction 
An exponential increase in high-impact imaging publications of 
LS has been seen in recent years. However, the majority of re- 
ent systematic reviews on the topic are technique-based ( Turner 
t al., 2012 ), classifying and discussing studies based on the speciﬁc 
maging method utilised, rather than highlighting common themes 
nd shared conclusions. Furthermore, comprehensive reviews of ALS 
maging have focused primarily on the achievements of landmark 
tudies, and are insufﬁciently critical of shortcomings, discussion of 
hich may contribute to improved study designs. 
ALS imaging has been relatively successful as a descriptive tool, 
haracterising features of speciﬁc ALS phenotypes and genotypes Abbreviations: AD, axial diffusivity; C9orf72, chromosome 9 open reading frame 72; 
TI, diffusion tensor imaging; FA, fractional anisotropy; MD, mean diffusivity; MEG, 
agnetoencephalography; MRS, magnetic resonance spectroscopy; MUNE, motor unit 
umber estimation; PET, positron emission tomography; PNS, peripheral nervous sys- 
em; RD, radial diffusivity; ROI, region of interest; SPECT, single photon emission com- 
uted tomography; TMS, transcranial magnetic stimulation; VBM, voxel-based mor- 
hometry. 
* Correspondence to: Peter Bede, Tel.: + 353 1 8964497; fax: + 353 1 2604787. 
E-mail address: bedepeter@hotmail.com (P. Bede). 
213-1582/ $ - see front matter c © 2014 The Authors. Published by Elsevier Inc. This is an
icenses / by-nc-nd / 3.0 / ). 
ttp://dx.doi.org/10.1016/j.nicl.2014.02.011 ( Chang et al., 2005 ; Stanton et al., 2009a ; Bede et al., 2013a ). Ad- 
ditionally, the anatomical bases of recent clinical observations, such 
as the concept of cortical focality, neuropsychological deﬁcits, ex- 
trapyramidal dysfunction, and sensory deﬁcits, have been elucidated. 
Imaging studies of ALS have also contributed to our understanding 
of active biological processes, such as conﬁrmation of inﬂammatory 
mechanisms ( Corcia et al., 2012 ), spread along functional connec- 
tions ( Verstraete et al., 2013 ), and dysfunction of inhibitory circuits 
( Douaud et al., 2011 ). Recent work has provided evidence of network 
degeneration as opposed to preferential, focal white and grey mat- 
ter pathology ( Douaud et al., 2011 ). Landmark studies of presymp- 
tomatic genetic variants such as SOD-1 mutation carriers have high- 
lighted structural and metabolic changes prior to symptom onset and 
have offered unprecedented insights into the presymptomatic phase 
of the disease ( Ng et al., 2008 ; Carew et al., 2011 ). PET and fMRI 
studies have revealed compensatory processes, suggestive of an at- 
tempted functional adaptation in the face of relentless neurodegen- 
eration ( Schoenfeld et al., 2005 ). 
However as in the case of Alzheimer’s disease and multiple scle- 
rosis, the development of viable diagnostic, prognostic and disease 
progression markers at an individual level remains as one of the pri- 
mary aspirations of ALS. Despite years of research, progress on this 
front has been relatively slow, results inconsistent, and the outcomes  open access article under the CC BY-NC-ND license ( http: // creativecommons.org / 
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 not readily transferable to the clinic. The aims of this study are to
explore the factors that have led to a large number of inconsistent re-
sults and to reﬂect on optimal study designs which could be utilised
in future multi-centre studies. 
2. Methods 
A formal literature review was conducted on PubMed with the
individual search terms ‘Imaging ’ , ‘Neuroimaging ’ , ‘Magnetic reso-
nance imaging ’ , ‘Positron emission tomography ’ , ‘Single photon emis-
sion computed tomography ’ , ‘Diffusion tensor imaging ’ , ‘Voxel-based
morphometry ’ , ‘Spectroscopy ’ in combination with ‘ALS ’ and ‘Mo-
tor neuron disease ’ separately. Publications were searched during a
2 month period between November 2013 and December 2013. Both
original contributions and review papers ( Turner et al. , 2009 , 2012 ,
2013 ; Bede et al., 2012 ; Bowser et al., 2011 ; Turner and Modo, 2010 ;
Foerster et al., 2013b ; Wang et al., 2011 ; Agosta et al., 2010a ; Pradat
and Dib, 2009 ; van der Graaff et al., 2009 ; Dengler et al., 2005 ; Kalra
and Arnold, 2003 ; Karitzky and Ludolph, 2001 ; Comi et al., 1999 ;
Kollewe et al., 2012 ; Kassubek et al., 2012 ; Prell and Grosskreutz,
2013 ) were selected, but only articles published in English were
reviewed. Where relevant, references of identiﬁed papers were also
evaluated. Based on the above search criteria, a total of 184 original re-
search papers and 21 review papers were identiﬁed ( Supplementary
Table 1 ). Each original contribution was individually reviewed for
author-reported and reviewer-identiﬁed study limitations, based on
which distinct trends of common methodological shortcomings were
observed. An additional objective was to identify reports of seem-
ingly inconsistent results or potentially contradicting conclusions.
Thirdly, constructive examples of innovative methods were sought
in response to the identiﬁed stereotypical pitfalls, so that recommen-
dations for optimised ALS study designs can be presented. 
3. Results 
3.1. Common methodological limitations 
While disease heterogeneity is an inherent challenge of the ﬁeld,
common methodological study limitations can also be identiﬁed
across individual studies, such as small sample sizes, lack of dis-
ease controls, suboptimal patient characterisation, technique-driven
rather than clinical problem-driven studies, lenient statistical models
and insufﬁcient discussion of laterality and symmetry of pathology
( Table 1 ). In addition to the methodological shortcomings of single
studies, fairly well-deﬁned gaps in the ALS imaging literature as a
whole can also be observed, indicating pressing, yet promising re-
search opportunities ( Table 1 ). 
3.2. Inconsistencies of conclusions 
The above factors are likely to have contributed to the inconsis-
tencies of various studies, particularly in the degree of extra-motor
involvement, laterality of pathology and the extent of brain changes
in lower motor neuron dominant conditions. Many studies have
highlighted right precentral gyrus changes ( Kassubek et al., 2005 ;
Grossman et al., 2008 ; Agosta et al., 2007 ; Grosskreutz et al., 2006
), while others have demonstrated bilateral motor cortex pathol-
ogy ( Chang et al., 2005 ; Filippini et al., 2010 ; Verstraete et al., 2012 ;
Thivard et al., 2007 ; Bede et al., 2013c ). . Unilateral left ( Bede et al.,
2013c ) and right ( Mezzapesa et al., 2007 ) parahippocampal patholo-
gies have both been reported. Similar discrepancies can be observed
in studies of speciﬁc phenotypes. For example, relative sparing of
corticospinal tract integrity has been reported in progressive mus-
cle atrophy by some studies ( Cosottini et al., 2005b ), while others
have identiﬁed extensive diffusivity changes in the brain, concluding
that widespread CNS involvement occurs ( Prudlo et al., 2012 ). Andwhile some drug-response studies have captured a Riluzole effect
( Kalra et al., 2006 ), others failed to replicate this ( Bradley et al., 1999
). Accounts of extra-motor grey matter pathology also show con-
siderable variation ranging from limited frontotemporal pathology
to widespread occipital, parietal and subcortical changes. This wide
range of inconsistent ﬁndings may reﬂect true disease heterogeneity,
but is more likely to be a function of small sample size, inadequate
power, and consequent over-interpretation of ﬁndings. 
3.3. Sample size and statistical analysis 
The challenges of recruiting large patient cohorts in ALS imaging
studies are obvious due to disease-speciﬁc factors such as orthopnoea,
dyspnoea, and sialorrhoea. Yet, despite these recognised limitations,
formal power calculations are seldom carried out. Methods for power
calculations depend on the speciﬁc imaging technique utilised. Recent
evidence suggests that the number of foci reported in small VBM
studies and even in meta-analyses with few studies may often be
exaggerated ( Fusar-Poli et al., 2013 ). In contrast, whole-brain meta-
analyses of large sample sizes identify fewer foci than single studies
( Fusar-Poli et al., 2013 ). Region of interest (ROI) based studies, on the
other hand, are susceptible to strong reporting bias ( Ioannidis, 2011 ).
Methods for bias-corrected power calculations have been speciﬁcally
developed for diffusion tensor imaging ( Lauzon and Landman, 2013 ).
Sample size and power calculations for fMRI studies are relatively well
established ( Mumford, 2012 ; Desmond and Glover, 2002 ). Several
commercial software packages also exist for power calculations of
imaging studies ( Joyce and Hayasaka, 2012 ). 
The number of ALS patients included in SPECT studies varies be-
tween n = 14 ( Waldemar et al., 1992 ) and n = 26 ( Abe et al., 1997 ),
and those in PET studies varies between n = 7 ( Hoffman et al., 1992 )
and n = 32 ( Cistaro et al., 2012 ). Single-centre morphometric studies
of ALS also show considerable variation in sample size; from n = 12
( Minnerop et al., 2009 ) to n = 45 ( Verstraete et al., 2012 ). Similarly,
diffusivity studies report results from a range of sample sizes; from
n = 13 ( Ciccarelli et al., 2006 ) to n = 87 ( Rajagopalan et al., 2013 ).
In general, task (paradigm) based functional MRI studies are particu-
larly small; from n = 6 ( Schoenfeld et al., 2005 ) to n = 22 ( Mohammadi
et al., 2011 ). Resting state fMRI studies are somewhat larger; from
n = 12 ( Verstraete et al., 2010a ) to n = 25 ( Douaud et al., 2011 ). Spec-
troscopy studies range from n = 8 ( Yin et al., 2004 ) to n = 70 ( Pohl
et al., 2001 ; Block et al., 2002 ). Studies of speciﬁc genotypes and
phenotypes often draw conclusions from even smaller – frequently
single digit – sample sizes ( Table 2 ). 
The majority of ALS imaging papers use age and gender matched
study groups. Age is sometimes included as a covariate in the anal-
yses, but gender, education and handedness are seldom considered.
The effect of gender on MR variables is well established in healthy
populations ( Chen et al., 2007 ; Menzler et al., 2011 ) and can also be
demonstrated in ALS cohorts ( Bede et al., 2013b ). Similarly, the link
between handedness and corticospinal tract / motor cortex asymme-
try has been conﬁrmed in healthy individuals ( Herv ´e et al., 2009 ). In
ALS, there is evidence that handedness may be associated with side
of onset in ALS ( Turner et al., 2011 ), therefore correction for handed-
ness in ALS imaging studies may be judicious. Moreover, neuroimag-
ing data from healthy aging cohorts also demonstrate the effect of
education on structural data, especially in older populations which
are typically studied in ALS ( Arenaza-Urquijo et al., 2013 ; Noble et al.,
2012 ). The typically small sample sizes of ALS imaging studies are
often further subdivided to characterise speciﬁc phenotypes, which is
likely to accentuate the confounding effects of the above demographic
factors even more. 
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Table 1. 
Common shortcomings for ALS imaging studies. 
Common methodological limitations of individual ALS imaging studies 
• Technique-driven rather than clinical problem-driven studies 
• Conﬁrmatory as opposed to original study designs 
• Small to moderate sample sizes, lack of power calculations 
• Inadequate discussion or interpretation of unilateral ﬁndings 
• Suboptimal clinical patient characterisation 
• Lack of comprehensive genotyping i.e. C9orf72 which may contribute to extra-motor changes 
• Limited imaging methods i.e. white matter only, grey matter only studies, as opposed to multifaceted, multimodal structural / functional, cortical / subcortical characterisation 
• Lack of disease controls and “ALS-mimic” controls 
• Correlation of brain changes with clinical measures that also heavily depend on lower motor neuron function (ALSFRS-r, tapping rates) 
• Lack of post-mortem validation of imaging ﬁndings 
• Lenient statistical models, insufﬁcient correction for demographic factors (education, handedness, age, gender) 
• Reports of statistical “trends” uncorrected for multiple testing 
Shortcomings of the current literature of ALS imaging 
• Paucity of presymptomatic studies 
• Paucity of classiﬁer (diagnostic) studies 
• Paucity of meta-analyses 
• Paucity of high-ﬁeld MRI studies 
• Lack of large, cross-platform, multi-centre studies 
• Lack of post-mortem imaging studies in ALS 
• Relative paucity of spinal cord studies 
• Lack of quantitative LMN / plexus / PNS imaging studies 
• Paucity of muscle imaging studies 
Table 2 
A selection of sample size examples from imaging studies characterising speciﬁc ALS phenotypes or genotypes. The highlighted studies also included larger reference groups of 
controls or sporadic ALS patients. 
ALS-dementia 
n = 4 ( Neary et al., 1990 ; Tanaka et al., 1993 ), n = 8 ( Talbot et al., 1995 ), n = 17 ( Rajagopalan et al., 2013 ) 
ALS-PD-Guam complex 
n = 4 ( Snow et al., 1990 ) 
ALS-FTD 
n = 10 ( Chang et al., 2005 ), n = 12 ( Cistaro et al, 2014 ) 
D90a-SOD1 genotype 
n = 6 ( Stanton et al., 2009b ), n = 7 ( Blain et al., 2011 ; Turner et al., 2007a ), n = 10 ( Turner et al., 2005 ) 
C9orf72 hexanucleotide repeat expansion in ALS 
n = 9 ( Bede et al., 2013a ; Bede et al., 2013d ), n = 15 ( Cistaro et al., 2014 ) 
Progressive lateral sclerosis 
n = 4 ( Turner et al., 2007b ), n = 6 ( Ciccarelli et al., 2009 ; Mitsumoto et al., 2007 ), n = 12 ( van der Graaff et al., 2011 ), n = 19 ( Iwata et al., 2011 ) 
Progressive muscular atrophy 
n = 8 ( Cosottini et al., 2005a ), n = 9 ( Mitsumoto et al., 2007 ), n = 12 ( van der Graaff et al., 2011 ) 
Presymptomatic studies of homozygous D90A-SOD1 
n = 2 ( Turner et al., 2005 ), n = 8 ( Ng et al., 2008 ), n = 24 ( Carew et al., 2011 ) 
Bulbar onset ALS 
n = 8 ( Ellis et al., 2001 ; Ellis et al., 1998 ), n = 12 ( van der Graaff et al., 2011 ), n = 13 ( Cistaro et al., 2012 ), n = 13 ( Bede et al., 2013c ) 
Spinal onset ALS 
n = 8 ( Ellis et al., 2001 ; Ellis et al., 1998 ), n = 12 ( van der Graaff et al., 2011 ), n = 19 ( Cistaro et al., 2012 ), n = 20 ( Bede et al., 2013c ) 
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b.4. Disease controls 
Neurological disease controls, patients with lower motor neu- 
on syndromes ( Sperfeld et al., 2005 ), Kennedy’s disease patients 
 Sperfeld et al., 2005 ), Alzheimer’s disease cohorts ( Block et al., 2002 
 and poliomyelitis groups ( Dalakas et al., 1987 ) have been previ- 
usly included in ALS imaging studies. However, the large majority 
f ALS imaging studies utilise healthy controls as a reference group 
o highlight ALS-speciﬁc changes. For the development of diagnostic 
arkers capable of discriminating ALS from other neurological con- 
itions, the inclusion of disease controls, especially common mimics 
f ALS, is essential. 
.5. Laterality of ﬁndings 
Unilateral or asymmetrical imaging ﬁndings are frequently re- 
orted in ALS, yet they are seldom discussed comprehensively. Sim- 
larly to other neurodegenerative conditions, at an individual level, 
symmetrical symptoms and brain pathology are established features 
f early stage ALS ( Turner et al., 2011b ). However, few imaging stud- 
es have examined the relationship of sidedness of symptoms and 
rain changes. Metabolite ratio changes in the motor cortex have been shown to correspond to the lateralisation of clinical symptoms 
( Pohl et al., 2001 ; Block et al., 2002 ). Morphometric studies report 
unilateral pathological changes in the left cingulum ( Abrahams et al., 
2005 ), left middle frontal gyrus ( Kassubek et al., 2005 ), left inferior 
frontal gyrus ( Agosta et al., 2007 ), left thalamus ( Chang et al., 2005 ), 
left medial frontal region ( Kassubek et al., 2005 ), left insula ( Thivard 
et al., 2007 ), left anterior temporal region ( Grossman et al., 2008 ), left 
parahippocampal gyrus ( Bede et al., 2013c ), right parahippocampal 
gyrus ( Mezzapesa et al., 2007 ), right precentral gyrus ( Kassubek et al., 
2005 ; Grossman et al., 2008 ; Agosta et al., 2007 ; Grosskreutz et al., 
2006 ), right superior temporal gyrus ( Bede et al., 2013c ; Mezzapesa 
et al., 2007 ), right cerebellum ( Thivard et al., 2007 ), and right premo- 
tor regions ( Grossman et al., 2008 ). Diffusivity studies have reported 
unilateral pathology in the left inferior frontal lobe ( Canu et al., 2011 
) and right uncinate fasciculus ( Agosta et al., 2010b ). However, sam- 
ple size effects, handedness, disability proﬁle, disease duration and 
physiological CNS asymmetry are rarely considered in the interpre- 
tation of these unilateral ﬁndings. This is despite the recognition of 
physiological brain asymmetry in right-handed healthy populations 
( Takao et al., 2011 ) and that asymmetry of the primary motor cortex 
and corticospinal tract architecture is particularly well established 
P. Bede, O. Hardiman / NeuroImage: Clinical 4 (2014) 436–443 439 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ( Westerhausen et al., 2007 ). Sample size limitations, disability pro-
ﬁle and disease duration are likely to be the key factors contributing
to asymmetrical ﬁndings. It is probable that asymmetry decreases
on longitudinal follow-up. Until large meta-analyses and prospec-
tive studies with extensive data sharing are undertaken, reports on
laterality should be interpreted with caution, and emphasis should
be placed on the speciﬁc structure affected rather than the side of
involvement. 
3.6. Patient characterisation 
Multifaceted characterisation of patients is of importance given
the unique clinical, psychological and imaging proﬁle of speciﬁc ALS
genotypes, such as those with SOD1 mutations ( Stanton et al., 2009a ;
Blain et al., 2011 ; Turner et al., 2005 ) and those carrying the hexanu-
cleotide expansion in C9orf72 ( Bede et al., 2013a ). Imaging studies
of ALS often provide in-depth characterisation in selected domains
e.g. detailed psychological and limited genetic or post-mortem pro-
ﬁling, or vice versa. This is frequently a function of local expertise and
is likely to improve with the shared infrastructure of international
collaborations. 
3.7. Multimodal studies 
In studies using whole-brain, functional imaging modalities, such
as PET, SPECT or fMRI, single-technique approaches may be sufﬁ-
cient. However, in studies using region-of-interest (ROI) or segmen-
tation based MRI techniques such as VBM, DTI or cortical thickness
measurements, multimodal approaches may be superior by providing
comprehensive characterisation of disease-speciﬁc pathology. Stud-
ies combining multiple imaging techniques that evaluate multiple
measures of both grey and white matter integrity are more likely
to capture the full spectrum of network degeneration in ALS. Mul-
timodal papers have highlighted increased functional and decreased
structural connectivity in ALS, suggesting inhibitory dysfunction in
ALS ( Douaud et al., 2011 ). The beneﬁt of using multiple imaging
parameters can be further illustrated with the use of multiple diffu-
sivity variables. Many DTI studies only use fractional anisotropy (FA)
or mean diffusivity (MD), despite the fact that these are composite
measures of eigenvalues and are not associated with the speciﬁc na-
ture of white matter pathology. Conversely, axial diffusivity (AD) and
radial diffusivity (RD) are independent variables; AD is broadly con-
sidered an axonal marker ( Sun et al., 2006 ) and RD a myelin marker
( Song et al., 2005 ). Multimodal biomarker studies are also ideal as a
method to compare the sensitivity and speciﬁcity proﬁles of various
techniques. For example, multimodal studies have suggested that MR
spectroscopy may be more sensitive in detecting UMN degeneration
than TMS ( Kaufmann et al., 2004 ). 
A large longitudinal multimodal ALS study utilising DTI, MUNE,
MRS and TMS has concluded that MUNE changes considerably over
time in comparison with other markers (DTI, TMS) that showed less
signiﬁcant longitudinal changes ( Mitsumoto et al., 2007 ). Multimodal
studies are also optimal cross-validation platforms, establishing novel
imaging approaches such as whole-brain MRS against more recog-
nised techniques ( Govind et al., 2012 ). Whole brain MR spectroscopy
demonstrated that metabolic changes along the corticospinal tracts
correlate with more established measures of CST integrity ( Stagg et al.,
2013 ). Multimodal approaches are also essential in diagnostic, clas-
siﬁer analyses. Discriminant analyses utilising multiple imaging vari-
ables have been consistently shown to improve the sensitivity and
speciﬁcity of group classiﬁcation ( Filippini et al., 2010 ). 
3.8. Presymptomatic studies 
Very few studies have examined presymptomatic carriers of ALS
causing mutations to date ( Ng et al., 2008 ; Carew et al., 2011 ; Turneret al., 2005 ). In a large spectroscopy study of presymptomatic SOD1
carriers, metabolic changes were detected in the spinal cord prior
to development of symptoms ( Carew et al., 2011 ). A landmark DTI
study of asymptomatic SOD1 carriers identiﬁed decreased fractional
anisotropy and increased radial diffusivity in the posterior limb of
the internal capsule compared to healthy SOD1 negative controls ( Ng
et al., 2008 ). These pioneering studies should help to pave the way
for future studies, so this relatively arcane, presymptomatic phase
of ALS, representing a crucially important diagnostic and therapeutic
window, can be explored. 
3.9. Multicentre ALS imaging studies 
The Neuroimaging Society in ALS (NISALS) had its founding meet-
ing in 2010 attracting considerable technical, clinical, psychology,
and imaging expertise from various centres around the world. The
challenges, objectives and potential beneﬁts of multicentre collab-
oration in ALS imaging have been candidly discussed ( Turner et al.,
2011a ). Another example of a multicentre ALS imaging and biomarker
initiative is the SOPHIA 99 Consortium of the European Union Neu-
rodegenerative Disease Research Programme (JPND). The obvious ad-
vantage of such collaborations is generating large patient numbers
of relatively rare ALS phenotypes. The challenges of such initiatives
include harmonisation across different scanner ﬁeld-strengths and
manufacturers, funding and authorship issues, time contribution of
participating individuals, data management, storage and protection,
ethics approvals, etc. Despite these difﬁculties however, multicentre
neuroimaging is routinely used in clinical trials of multiple sclerosis
drugs with established cross-platform harmonisation and calibration
protocols ( Moraal et al., 2009 ). Multicentre MR studies have also
been successfully conducted in Alzheimer’s disease, as evidenced by
the Alzheimer’s Disease Neuroimaging Initiative (ADNI). The cross
platform calibration of ADNI, utilising travelling MRI phantoms has
been comprehensively described ( Gunter et al., 2009 ). By contrast,
few cross-platform ALS imaging studies have been published to date.
A large two-centre imaging study of ALS and ALS-FTD has been con-
ducted in Germany using identical scanners and imaging protocol
( Schuster et al., 2013 ), and the First NISALS coordinated DTI project is
currently underway with the participation of 12 European and North
American centres. 
3.10. Meta-analyses 
While meta-analyses could potentially presage the sort of infor-
mation large multicentre studies can offer, surprisingly few meta-
analyses have been carried out in ALS. An individual patient data (IPD)
meta-analysis of DTI data of 221 ALS patients and 187 healthy controls
suggested that corticospinal tract DTI alone lacked diagnostic speci-
ﬁcity ( Foerster et al., 2013a ). However, a voxel-based meta-analysis
of DTI date from eight studies, comprising 143 ALS patients and 145
healthy controls highlighted bilateral corticospinal tract changes in
the posterior limb of the internal capsule as well as bilateral frontal
and cingulate diffusivity changes ( Li et al., 2012 ). A meta-analysis of 5
VBM studies demonstrated that right precentral grey matter atrophy
is an important feature of ALS ( Chen and Ma 2010 ). The data reposito-
ries of multicentre MRI initiatives of ALS, such as NISALS and SOPHIA,
will be ideal platforms for individual patient data meta-analyses. 
3.11. Correlative studies 
A number of ALS imaging studies have sought to correlate com-
mon clinical variables with various MRI measures. Decreased corti-
cospinal tract FA ( Thivard et al., 2007 ; Cosottini et al., 2005a ) has
been associated with decreased ALSFRS-r ( Cedarbaum et al., 1999 ),
composite upper motor neuron scores ( Stanton et al., 2009a ; Filippini
et al., 2010 ; Blain et al., 2011 ) and disease progression rates ( Ciccarelli
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e
(  
e
t
)
c
i
A
t
t
t
l
n
d
t
o
i
T
ﬁ
t
d
a
3
t
d
B
c
i
c
I
a
s
(
c
f
(
3
p
o
d
d
i
i
A
c
p
t
i
s
e
p
a
e
o
t
m
t
pt al. , 2006 , 2009 ; Agosta et al., 2010b ). Grey matter density measures 
 Grosskreutz et al., 2006 ; Bede et al., 2013c ) and NAA / Cr ratios ( Siv ´ak
t al., 2010 ) have been correlated with disability scores. In addition 
o motor variables, cognitive ( Grossman et al., 2008 ; Sarro et al., 2011 
 and behavioural ( Tsujimoto et al., 2011 ) deﬁcits have also been 
orrelated to structural changes in ALS. 
Despite the abundance of clinically-correlated neuroimaging stud- 
es in ALS, important conceptual factors must be considered. The 
LSFRS-r is heavily inﬂuenced by lower motor neuron degenera- 
ion which is not captured by current imaging technology. Correla- 
ion of disease duration with structural changes is relatively difﬁcult 
o interpret, as progression rates vary considerably at an individual 
evel. Contrary to the conclusions of some studies, imaging should 
ot be proposed as an alternative clinical assessment tool. Clinical 
isability scales and neuropsychological tests can be easily and rou- 
inely applied in a clinic room, home or bedside setting. They reﬂect 
n key functional aspects of the disability and with minimal train- 
ng, excellent inter-rater and test–retest reliability can be achieved. 
he role of imaging in ALS on the other hand points beyond simpli- 
ed clinico-structural correlations and could be regarded as a sensi- 
ive and objective descriptive tool, able to capture subtle, phenotype- 
eﬁning pathology in cross-sectional and longitudinal, group-level 
nd individual-level analyses. 
.12. Diagnostic applications 
There is considerable interest in developing imaging technology 
hat can discriminate ALS from non-ALS and mimic syndromes at in- 
ividual level. Discriminant analyses of diffusivity measures ( Ben 
ashat et al., 2011 ), machine-learning and support vector machine 
lassiﬁer-analyses ( Wang and Summers, 2012 ), are increasingly used 
n other neurodegenerative conditions ( Orr `u et al., 2012 ) and show 
onsiderable promise in the interpretation of individual imaging data. 
n ALS, a discriminant analysis, combining radial diffusivity, fractional 
nisotropy and voxel-based morphometry, achieved study group clas- 
iﬁcation with 92% sensitivity, 88% speciﬁcity, and 90% accuracy 
 Filippini et al., 2010 ). The use of the disease state classiﬁer ma- 
hine learning approach (support-vector machine) on resting-state 
MRI data achieved over 71% accuracy for disease state classiﬁcation 
 Welsh et al., 2013 ). 
.13. Future directions 
The purpose of ALS imaging is twofold. The ﬁrst is to further 
rogress our understanding of disease pathology and pathophysi- 
logy, in which group analysis is appropriate; and the second is to 
evelop an imaging based technology that enhances individualised 
iagnostic accuracy beyond best clinical practice. Based on the crit- 
cal appraisal of the shortcomings and achievements of recent ALS 
maging studies, optimised study recommendations can be outlined. 
LS imaging studies should ideally encompass genetically, neuropsy- 
hologically, electrophysiologically, and pathologically characterised 
atient cohorts, a healthy reference group and disease controls. Mul- 
iple complementary imaging techniques should be ideally utilised 
n the same study to provide multifaceted grey and white matter as- 
essments. The effect of demographic variables, such as age, gender, 
ducation and handedness, should be strictly accounted for, and com- 
arisons of ALS sub-cohorts should be corrected for disease duration 
nd disability. Correlative studies should take the network degen- 
ration aspect of ALS into account and assess network integrity as 
pposed to selected grey or white matter measures. Individual pa- 
ient data meta-analyses are required prior to initiating harmonised 
ulticentre studies, which in turn are eagerly awaited and are likely 
o generate sufﬁciently large sample sizes for meaningful data inter- 
retation. From a technological standpoint, high-ﬁeld MRI scanners i.e. 7 T 
systems are increasingly available, promising unprecedented resolu- 
tion and detailed spectroscopic evaluation. Nonetheless, only a few 
ALS studies have been carried out on these systems to date ( Verstraete 
et al., 2010 ; Kwan et al., 2012 ). Similarly, no post-mortem MRI stud- 
ies have been conducted in ALS, a method increasingly used in other 
neurodegenerative conditions. Quantitative muscle MRI is another 
relatively overlooked ﬁeld of ALS biomarker research ( Bryan et al., 
1998 ). Whole-brain MRS is a particularly promising technique and 
its potential in ALS is far from being fully explored ( Stagg et al., 2013 ). 
Despite a number of very successful spinal cord MRI studies ( Valsasina 
et al., 2007 ), quantitative spinal imaging methods seem surprisingly 
underutilised in ALS11. Finally, the emergence of combined PET / MRI 
scanners and access to magnetoencephalography (MEG) are other 
exciting developments which are likely to contribute to our under- 
standing of ALS pathophysiology. 
4. Conclusions 
A critical review of ALS imaging has identiﬁed stereotypical short- 
comings, the lessons of which should be considered in the design 
of future prospective MRI studies. At a time when large multicentre 
studies are underway a candid discussion of these factors is particu- 
larly timely. 
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